This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
Here's Why Investors Should Retain Abbott (ABT) Stock Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) on continued growth in Diabetes business and upbeat guidance.
Inspire Medical (INSP) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Inspire Medical's (INSP) global presence.
Masimo's (MASI) W1 to Boost Virtual Care in Preoperative Patients
by Zacks Equity Research
Masimo's (MASI) W1 advanced health-tracking watch is expected to provide better insights into pre-operative patients' heart rate variability data and improve pre-habilitation.
Abbott (ABT) FreeStyle Libre 2 Gets Reimbursement in France
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre increased reimbursement makes it possible for more people in France with diabetes to use the recent CGM technology.
Reasons to Retain QuidelOrtho (QDEL) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its product innovation aiding growth.
Boston Scientific's (BSX) New Launches Aid Amid Cost Pressure
by Zacks Equity Research
Boston Scientific (BSX) remains excited about the rest of 2023 and expects to continue to outpace its peers within the EMEA market.
Here's How Much a $1000 Investment in Boston Scientific Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
The Zacks Analyst Blog Highlights Pfizer, Philip Morris, American Tower, Boston Scientific and Northrop Grumman
by Zacks Equity Research
Pfizer, Philip Morris, American Tower, Boston Scientific and Northrop Grumman are included in this Analyst Blog.
Top Stock Reports for Pfizer, Philip Morris & American Tower
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), Philip Morris International Inc. (PM) and American Tower Corporation (AMT).
Quest Diagnostics' (DGX) New Buyout Expands Cancer Portfolio
by Zacks Equity Research
Quest Diagnostics (DGX) will use MRD technology to create new blood-based clinical lab services for solid tumour cancers that will be available starting in 2024.
Masimo's (MASI) Launch to Serve the Personalized Hearables Market
by Zacks Equity Research
Masimo's (MASI) new product offerings are expected to enable it to expand its footprint in the personalized hearables market.
Here's Why Buying Brookdale (BKD) Stock is a Prudent Move Now
by Zacks Equity Research
For the second quarter, Brookdale (BKD) expects RevPAR growth to be in the range of 11.5-12%.
Here's Why Hold Strategy is Apt for The Joint (JYNT) Stock Now
by Zacks Equity Research
The Joint (JYNT) is expected to keep growing due to rising patient visits and new clinic openings.
QIAGEN's (QGEN) ForenSeq MainstAY Workflow Gets FBI Nod
by Zacks Equity Research
QIAGEN's (QGEN) ForenSeq MainstAY workflow is a cost-effective substitute for analyzing short tandem repeats with capillary electrophoresis and facilitates volume casework for sexual assault cases.
Cardinal Health (CAH) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.
Avanos' (AVNS) Latest Buyout to Boost Its RF Product Offering
by Zacks Equity Research
Avanos' (AVNS) latest acquisition is expected to strengthen its foothold with a comprehensive suite of RF offerings.
The Joint (JYNT) Buys Wisconsin Regional Developer Zone Rights
by Zacks Equity Research
The Joint (JYNT) expects the Wisconsin region to hold a total of 53 clinics, of which 21 are currently operating.
Align's (ALGN) Invisalign Sales Grow Globally Amid Margin Woe
by Zacks Equity Research
Align (ALGN) is confident about a largely untapped market opportunity for digital orthodontics and restorative dentistry.
3 Reasons to Add HealthEquity (HQY) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about HealthEquity's (HQY) strength in HSA.
PacBio's (PACB) New Tie-Up to Boost Rare Disease Research
by Zacks Equity Research
PacBio's (PACB) latest collaboration is expected to highlight the feasibility and cost-effectiveness of using its HiFi sequencing technology.
Orthofix (OFIX) Advances in ALIF Procedure With New Launch
by Zacks Equity Research
Orthofix (OFIX) WaveForm A interbody features a wave-like design, providing a balance of strength, porosity and stability, along with a large implant graft aperture for bone graft material.
Quest Diagnostics (DGX) Partners to Offer New Testing Service
by Zacks Equity Research
Quest Diagnostics' (DGX) latest test indicates how different genes and their variants affect how a person reacts to drugs.
Here's Why You Should Buy Boston Scientific (BSX) Stock
by Zacks Equity Research
Investors are optimistic about Boston Scientific's (BSX) strong improvement in organic sales, indicating a solid rebound in the legacy business.
Humana (HUM) Sees Insurance Costs at Upper Limit of Guidance
by Zacks Equity Research
Despite the rising demand for elective procedures, Humana (HUM) sticks to its earnings guidance.
3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO) due to its R&D edge.